Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
暂无分享,去创建一个
V. Haddad | B. Escudier | J. Lumbroso | C. Théodore | Y. Loriot | A. Laplanche | K. Fizazi | P. Beuzeboc | C. Massard | J. Bouzy | E. Tournay | M. di Palma | M. Di Palma | M. Gross‐Goupil | M. Gross-Goupil
[1] X. Mariette,et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R de Crevoisier,et al. The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] C. Logothetis,et al. Phase I study of concurrent weekly docetaxel (Tax) and repeated 153Sm-lexidronam (Sam) in androgen-independent prostate cancer (AIPC) , 2008 .
[4] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Fizazi,et al. The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Pignon,et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.
[8] N. James,et al. 3LB ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases , 2007 .
[9] Elizabeth Garrett-Mayer,et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Parker,et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.
[11] C. Sternberg,et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial , 2007 .
[12] T. DeWeese,et al. Phase I trial of docetaxel (D) plus samarium153 (Sm 153) in patients (pts) with hormone refractory prostate cancer (HRPC) , 2007 .
[13] S. Larson,et al. Phase I study of docetaxel and 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC) , 2007 .
[14] A. Ravaud,et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] D. Vaughn,et al. Poor-prognosis germ cell tumors: we have not yet crossed the finish line. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Podoloff,et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Poupon,et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] David C. Smith,et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[20] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[21] F. Saad,et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.
[22] P. Ell,et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. , 2004, Urology.
[23] E. Small,et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Collette,et al. Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group , 2003 .
[25] M. Parmar,et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.
[26] I. Tannock,et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Fosså,et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. , 2003, International journal of radiation oncology, biology, physics.
[28] C. Logothetis,et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] L. Collette,et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. , 2003, European urology.
[30] G. Petrilli,et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] G D Roodman,et al. Biology of osteoclast activation in cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Wood,et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. , 2001, Cancer research.
[33] Terry L. Smith,et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial , 2001, The Lancet.
[34] B. Freidlin,et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Kantoff,et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[37] R. Lerski,et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] G. Hudes. Estramustine-based chemotherapy. , 1997, Seminars in urologic oncology.
[39] K. Tew,et al. Interaction of estramustine with tubulin isotypes. , 1997, Biochemistry.
[40] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] K. Tew,et al. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. , 1994, Molecular pharmacology.
[42] D P Dearnaley,et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[43] B. Dahllöf,et al. Estramustine depolymerizes microtubules by binding to tubulin. , 1993, Cancer research.
[44] J. Crook,et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.
[45] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[46] K. Rothman. Estimation of confidence limits for the cumulative probability of survival in life table analysis. , 1978, Journal of chronic diseases.
[47] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .